These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 10840005)

  • 1. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
    Boersma E; Pieper KS; Steyerberg EW; Wilcox RG; Chang WC; Lee KL; Akkerhuis KM; Harrington RA; Deckers JW; Armstrong PW; Lincoff AM; Califf RM; Topol EJ; Simoons ML
    Circulation; 2000 Jun; 101(22):2557-67. PubMed ID: 10840005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
    Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
    Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and outcome after acute coronary syndromes without persistent ST-segment elevation.
    Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Harrington RA
    Am Heart J; 2000 May; 139(5):858-66. PubMed ID: 10783220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
    Akkerhuis KM; Maas AC; Klootwijk PA; Krucoff MW; Meij S; Califf RM; Simoons ML
    J Electrocardiol; 2000 Apr; 33(2):127-36. PubMed ID: 10819406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
    Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
    Mahaffey KW; Harrington RA; Simoons ML; Granger CB; Graffagnino C; Alberts MJ; Laskowitz DT; Miller JM; Sloan MA; Berdan LG; MacAulay CM; Lincoff AM; Deckers J; Topol EJ; Califf RM
    Circulation; 1999 May; 99(18):2371-7. PubMed ID: 10318656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial.
    Fintel DJ; Ledley GS
    Clin Cardiol; 2000 Sep; 23 Suppl 5(Suppl 5):V1-12. PubMed ID: 11019716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Labinaz M; Kilaru R; Pieper K; Marso SP; Kitt MM; Simoons ML; Califf RM; Topol EJ; Armstrong PW; Harrington RA
    Circulation; 2002 Jan; 105(3):322-7. PubMed ID: 11804987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
    Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
    N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
    McClure MW; Berkowitz SD; Sparapani R; Tuttle R; Kleiman NS; Berdan LG; Lincoff AM; Deckers J; Diaz R; Karsch KR; Gretler D; Kitt M; Simoons M; Topol EJ; Califf RM; Harrington RA
    Circulation; 1999 Jun; 99(22):2892-900. PubMed ID: 10359733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
    Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
    Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
    N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
    Akkerhuis KM; Deckers JW; Boersma E; Harrington RA; Stepinska J; Mahaffey KW; Wilcox RG; Lincoff AM; Keltai M; Topol EJ; Califf RM; Simoons ML
    Eur Heart J; 2000 Mar; 21(5):371-81. PubMed ID: 10666351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation.
    Hasdai D; Harrington RA; Hochman JS; Califf RM; Battler A; Box JW; Simoons ML; Deckers J; Topol EJ; Holmes DR
    J Am Coll Cardiol; 2000 Sep; 36(3):685-92. PubMed ID: 10987585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes.
    Srichai MB; Jaber WA; Prior DL; Marso SP; Houghtaling PL; Menon V; Simoons ML; Harrington RA; Hochman JS;
    Am Heart J; 2004 Jan; 147(1):84-90. PubMed ID: 14691424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
    Roe MT; Harrington RA; Prosper DM; Pieper KS; Bhatt DL; Lincoff AM; Simoons ML; Akkerhuis M; Ohman EM; Kitt MM; Vahanian A; Ruzyllo W; Karsch K; Califf RM; Topol EJ
    Circulation; 2000 Sep; 102(10):1101-6. PubMed ID: 10973837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
    Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
    Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.